

Covid-19 Impact on Global Scleroderma Therapeutics Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C00E9D3FAA89EN.html>

Date: June 2020

Pages: 130

Price: US\$ 3,900.00 (Single User License)

ID: C00E9D3FAA89EN

Abstracts

Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.

The market is mainly driven by the off-label use of drugs approved for its symptomatic indications, such as rheumatoid arthritis.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Scleroderma Therapeutics market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Scleroderma Therapeutics industry.

Based on our recent survey, we have several different scenarios about the Scleroderma Therapeutics YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US\$ 1394.4 million in 2019. The market size of Scleroderma Therapeutics will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Scleroderma Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Scleroderma Therapeutics market in terms of revenue. Players, stakeholders, and other participants in the global Scleroderma Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Regional and Country-level Analysis

The report offers an exhaustive geographical analysis of the global Scleroderma Therapeutics market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Scleroderma Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Scleroderma Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Scleroderma Therapeutics market. The following players are covered in this report:

F. Hoffmann-La Roche AG

Bristol-Myers Squibb Company

Celgene Corporation

Argentis Pharmaceuticals, LLC

Bayer AG

Boehringer Ingelheim International GmbH

Akashi Therapeutics

Prometic Life Sciences, Inc.

Emerald Health Pharmaceuticals

Kadmon Holdings, Inc.

Seattle Genetics, Inc.

Cytori Therapeutics, Inc.

Fibrocell Science, Inc.

Chemomab

Corbus Pharmaceuticals Holdings, Inc.

Genkyotex

Scleroderma Therapeutics Breakdown Data by Type

Immunosuppressors

Phosphodiesterase 5 Inhibitors - PHA

Endothelin Receptor Antagonists

Prostacyclin Analogues

Calcium Channel Blockers

Analgesics

Others

Scleroderma Therapeutics Breakdown Data by Application

Systemic

Localized

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered: Ranking by Scleroderma Therapeutics Revenue
- 1.4 Market Analysis by Type
 - 1.4.1 Global Scleroderma Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
 - 1.4.2 Immunosuppressors
 - 1.4.3 Phosphodiesterase 5 Inhibitors - PHA
 - 1.4.4 Endothelin Receptor Antagonists
 - 1.4.5 Prostacyclin Analogues
 - 1.4.6 Calcium Channel Blockers
 - 1.4.7 Analgesics
 - 1.4.8 Others
- 1.5 Market by Application
 - 1.5.1 Global Scleroderma Therapeutics Market Share by Application: 2020 VS 2026
 - 1.5.2 Systemic
 - 1.5.3 Localized
- 1.6 Coronavirus Disease 2019 (Covid-19): Scleroderma Therapeutics Industry Impact
 - 1.6.1 How the Covid-19 is Affecting the Scleroderma Therapeutics Industry
 - 1.6.1.1 Scleroderma Therapeutics Business Impact Assessment - Covid-19
 - 1.6.1.2 Supply Chain Challenges
 - 1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products
 - 1.6.2 Market Trends and Scleroderma Therapeutics Potential Opportunities in the COVID-19 Landscape
 - 1.6.3 Measures / Proposal against Covid-19
 - 1.6.3.1 Government Measures to Combat Covid-19 Impact
 - 1.6.3.2 Proposal for Scleroderma Therapeutics Players to Combat Covid-19 Impact
- 1.7 Study Objectives
- 1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

- 2.1 Scleroderma Therapeutics Market Perspective (2015-2026)
- 2.2 Scleroderma Therapeutics Growth Trends by Regions
 - 2.2.1 Scleroderma Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026

- 2.2.2 Scleroderma Therapeutics Historic Market Share by Regions (2015-2020)
- 2.2.3 Scleroderma Therapeutics Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
 - 2.3.1 Market Top Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Challenges
 - 2.3.4 Porter's Five Forces Analysis
 - 2.3.5 Scleroderma Therapeutics Market Growth Strategy
 - 2.3.6 Primary Interviews with Key Scleroderma Therapeutics Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

- 3.1 Global Top Scleroderma Therapeutics Players by Market Size
 - 3.1.1 Global Top Scleroderma Therapeutics Players by Revenue (2015-2020)
 - 3.1.2 Global Scleroderma Therapeutics Revenue Market Share by Players (2015-2020)
 - 3.1.3 Global Scleroderma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Scleroderma Therapeutics Market Concentration Ratio
 - 3.2.1 Global Scleroderma Therapeutics Market Concentration Ratio (CR5 and HHI)
 - 3.2.2 Global Top 10 and Top 5 Companies by Scleroderma Therapeutics Revenue in 2019
- 3.3 Scleroderma Therapeutics Key Players Head office and Area Served
- 3.4 Key Players Scleroderma Therapeutics Product Solution and Service
- 3.5 Date of Enter into Scleroderma Therapeutics Market
- 3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

- 4.1 Global Scleroderma Therapeutics Historic Market Size by Type (2015-2020)
- 4.2 Global Scleroderma Therapeutics Forecasted Market Size by Type (2021-2026)

5 SCLERODERMA THERAPEUTICS BREAKDOWN DATA BY APPLICATION (2015-2026)

- 5.1 Global Scleroderma Therapeutics Market Size by Application (2015-2020)
- 5.2 Global Scleroderma Therapeutics Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

- 6.1 North America Scleroderma Therapeutics Market Size (2015-2020)
- 6.2 Scleroderma Therapeutics Key Players in North America (2019-2020)
- 6.3 North America Scleroderma Therapeutics Market Size by Type (2015-2020)
- 6.4 North America Scleroderma Therapeutics Market Size by Application (2015-2020)

7 EUROPE

- 7.1 Europe Scleroderma Therapeutics Market Size (2015-2020)
- 7.2 Scleroderma Therapeutics Key Players in Europe (2019-2020)
- 7.3 Europe Scleroderma Therapeutics Market Size by Type (2015-2020)
- 7.4 Europe Scleroderma Therapeutics Market Size by Application (2015-2020)

8 CHINA

- 8.1 China Scleroderma Therapeutics Market Size (2015-2020)
- 8.2 Scleroderma Therapeutics Key Players in China (2019-2020)
- 8.3 China Scleroderma Therapeutics Market Size by Type (2015-2020)
- 8.4 China Scleroderma Therapeutics Market Size by Application (2015-2020)

9 JAPAN

- 9.1 Japan Scleroderma Therapeutics Market Size (2015-2020)
- 9.2 Scleroderma Therapeutics Key Players in Japan (2019-2020)
- 9.3 Japan Scleroderma Therapeutics Market Size by Type (2015-2020)
- 9.4 Japan Scleroderma Therapeutics Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

- 10.1 Southeast Asia Scleroderma Therapeutics Market Size (2015-2020)
- 10.2 Scleroderma Therapeutics Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Scleroderma Therapeutics Market Size by Type (2015-2020)
- 10.4 Southeast Asia Scleroderma Therapeutics Market Size by Application (2015-2020)

11 INDIA

- 11.1 India Scleroderma Therapeutics Market Size (2015-2020)

- 11.2 Scleroderma Therapeutics Key Players in India (2019-2020)
- 11.3 India Scleroderma Therapeutics Market Size by Type (2015-2020)
- 11.4 India Scleroderma Therapeutics Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

- 12.1 Central & South America Scleroderma Therapeutics Market Size (2015-2020)
- 12.2 Scleroderma Therapeutics Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Scleroderma Therapeutics Market Size by Type (2015-2020)
- 12.4 Central & South America Scleroderma Therapeutics Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 F. Hoffmann-La Roche AG

- 13.1.1 F. Hoffmann-La Roche AG Company Details
- 13.1.2 F. Hoffmann-La Roche AG Business Overview and Its Total Revenue
- 13.1.3 F. Hoffmann-La Roche AG Scleroderma Therapeutics Introduction
- 13.1.4 F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2015-2020)
- 13.1.5 F. Hoffmann-La Roche AG Recent Development

13.2 Bristol-Myers Squibb Company

- 13.2.1 Bristol-Myers Squibb Company Company Details
- 13.2.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
- 13.2.3 Bristol-Myers Squibb Company Scleroderma Therapeutics Introduction
- 13.2.4 Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2015-2020)
- 13.2.5 Bristol-Myers Squibb Company Recent Development

13.3 Celgene Corporation

- 13.3.1 Celgene Corporation Company Details
- 13.3.2 Celgene Corporation Business Overview and Its Total Revenue
- 13.3.3 Celgene Corporation Scleroderma Therapeutics Introduction
- 13.3.4 Celgene Corporation Revenue in Scleroderma Therapeutics Business (2015-2020)
- 13.3.5 Celgene Corporation Recent Development

13.4 Argentis Pharmaceuticals, LLC

- 13.4.1 Argentis Pharmaceuticals, LLC Company Details
- 13.4.2 Argentis Pharmaceuticals, LLC Business Overview and Its Total Revenue

- 13.4.3 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Introduction
- 13.4.4 Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2015-2020)
- 13.4.5 Argentis Pharmaceuticals, LLC Recent Development
- 13.5 Bayer AG
 - 13.5.1 Bayer AG Company Details
 - 13.5.2 Bayer AG Business Overview and Its Total Revenue
 - 13.5.3 Bayer AG Scleroderma Therapeutics Introduction
 - 13.5.4 Bayer AG Revenue in Scleroderma Therapeutics Business (2015-2020)
 - 13.5.5 Bayer AG Recent Development
- 13.6 Boehringer Ingelheim International GmbH
 - 13.6.1 Boehringer Ingelheim International GmbH Company Details
 - 13.6.2 Boehringer Ingelheim International GmbH Business Overview and Its Total Revenue
 - 13.6.3 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Introduction
 - 13.6.4 Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2015-2020)
 - 13.6.5 Boehringer Ingelheim International GmbH Recent Development
- 13.7 Akashi Therapeutics
 - 13.7.1 Akashi Therapeutics Company Details
 - 13.7.2 Akashi Therapeutics Business Overview and Its Total Revenue
 - 13.7.3 Akashi Therapeutics Scleroderma Therapeutics Introduction
 - 13.7.4 Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2015-2020)
 - 13.7.5 Akashi Therapeutics Recent Development
- 13.8 Prometic Life Sciences, Inc.
 - 13.8.1 Prometic Life Sciences, Inc. Company Details
 - 13.8.2 Prometic Life Sciences, Inc. Business Overview and Its Total Revenue
 - 13.8.3 Prometic Life Sciences, Inc. Scleroderma Therapeutics Introduction
 - 13.8.4 Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
 - 13.8.5 Prometic Life Sciences, Inc. Recent Development
- 13.9 Emerald Health Pharmaceuticals
 - 13.9.1 Emerald Health Pharmaceuticals Company Details
 - 13.9.2 Emerald Health Pharmaceuticals Business Overview and Its Total Revenue
 - 13.9.3 Emerald Health Pharmaceuticals Scleroderma Therapeutics Introduction
 - 13.9.4 Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2015-2020)

- 13.9.5 Emerald Health Pharmaceuticals Recent Development
- 13.10 Kadmon Holdings, Inc.
 - 13.10.1 Kadmon Holdings, Inc. Company Details
 - 13.10.2 Kadmon Holdings, Inc. Business Overview and Its Total Revenue
 - 13.10.3 Kadmon Holdings, Inc. Scleroderma Therapeutics Introduction
 - 13.10.4 Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
 - 13.10.5 Kadmon Holdings, Inc. Recent Development
- 13.11 Seattle Genetics, Inc.
 - 10.11.1 Seattle Genetics, Inc. Company Details
 - 10.11.2 Seattle Genetics, Inc. Business Overview and Its Total Revenue
 - 10.11.3 Seattle Genetics, Inc. Scleroderma Therapeutics Introduction
 - 10.11.4 Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
 - 10.11.5 Seattle Genetics, Inc. Recent Development
- 13.12 Cytori Therapeutics, Inc.
 - 10.12.1 Cytori Therapeutics, Inc. Company Details
 - 10.12.2 Cytori Therapeutics, Inc. Business Overview and Its Total Revenue
 - 10.12.3 Cytori Therapeutics, Inc. Scleroderma Therapeutics Introduction
 - 10.12.4 Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
 - 10.12.5 Cytori Therapeutics, Inc. Recent Development
- 13.13 Fibrocell Science, Inc.
 - 10.13.1 Fibrocell Science, Inc. Company Details
 - 10.13.2 Fibrocell Science, Inc. Business Overview and Its Total Revenue
 - 10.13.3 Fibrocell Science, Inc. Scleroderma Therapeutics Introduction
 - 10.13.4 Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
 - 10.13.5 Fibrocell Science, Inc. Recent Development
- 13.14 Chemomab
 - 10.14.1 Chemomab Company Details
 - 10.14.2 Chemomab Business Overview and Its Total Revenue
 - 10.14.3 Chemomab Scleroderma Therapeutics Introduction
 - 10.14.4 Chemomab Revenue in Scleroderma Therapeutics Business (2015-2020)
 - 10.14.5 Chemomab Recent Development
- 13.15 Corbus Pharmaceuticals Holdings, Inc.
 - 10.15.1 Corbus Pharmaceuticals Holdings, Inc. Company Details
 - 10.15.2 Corbus Pharmaceuticals Holdings, Inc. Business Overview and Its Total Revenue

- 10.15.3 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Introduction
- 10.15.4 Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
- 10.15.5 Corbus Pharmaceuticals Holdings, Inc. Recent Development
- 13.16 Genkyotex
 - 10.16.1 Genkyotex Company Details
 - 10.16.2 Genkyotex Business Overview and Its Total Revenue
 - 10.16.3 Genkyotex Scleroderma Therapeutics Introduction
 - 10.16.4 Genkyotex Revenue in Scleroderma Therapeutics Business (2015-2020)
 - 10.16.5 Genkyotex Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

- 15.1 Research Methodology
 - 15.1.1 Methodology/Research Approach
 - 15.1.2 Data Source
- 15.2 Disclaimer
- 15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Scleroderma Therapeutics Key Market Segments

Table 2. Key Players Covered: Ranking by Scleroderma Therapeutics Revenue

Table 3. Ranking of Global Top Scleroderma Therapeutics Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Scleroderma Therapeutics Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Immunosuppressors

Table 6. Key Players of Phosphodiesterase 5 Inhibitors - PHA

Table 7. Key Players of Endothelin Receptor Antagonists

Table 8. Key Players of Prostacyclin Analogues

Table 9. Key Players of Calcium Channel Blockers

Table 10. Key Players of Analgesics

Table 11. Key Players of Others

Table 12. COVID-19 Impact Global Market: (Four Scleroderma Therapeutics Market Size Forecast Scenarios)

Table 13. Opportunities and Trends for Scleroderma Therapeutics Players in the COVID-19 Landscape

Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 15. Key Regions/Countries Measures against Covid-19 Impact

Table 16. Proposal for Scleroderma Therapeutics Players to Combat Covid-19 Impact

Table 17. Global Scleroderma Therapeutics Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 18. Global Scleroderma Therapeutics Market Size by Regions (US\$ Million): 2020 VS 2026

Table 19. Global Scleroderma Therapeutics Market Size by Regions (2015-2020) (US\$ Million)

Table 20. Global Scleroderma Therapeutics Market Share by Regions (2015-2020)

Table 21. Global Scleroderma Therapeutics Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 22. Global Scleroderma Therapeutics Market Share by Regions (2021-2026)

Table 23. Market Top Trends

Table 24. Key Drivers: Impact Analysis

Table 25. Key Challenges

Table 26. Scleroderma Therapeutics Market Growth Strategy

Table 27. Main Points Interviewed from Key Scleroderma Therapeutics Players

Table 28. Global Scleroderma Therapeutics Revenue by Players (2015-2020) (Million US\$)

Table 29. Global Scleroderma Therapeutics Market Share by Players (2015-2020)

Table 30. Global Top Scleroderma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Therapeutics as of 2019)

Table 31. Global Scleroderma Therapeutics by Players Market Concentration Ratio (CR5 and HHI)

Table 32. Key Players Headquarters and Area Served

Table 33. Key Players Scleroderma Therapeutics Product Solution and Service

Table 34. Date of Enter into Scleroderma Therapeutics Market

Table 35. Mergers & Acquisitions, Expansion Plans

Table 36. Global Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 37. Global Scleroderma Therapeutics Market Size Share by Type (2015-2020)

Table 38. Global Scleroderma Therapeutics Revenue Market Share by Type (2021-2026)

Table 39. Global Scleroderma Therapeutics Market Size Share by Application (2015-2020)

Table 40. Global Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US\$)

Table 41. Global Scleroderma Therapeutics Market Size Share by Application (2021-2026)

Table 42. North America Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US\$)

Table 43. North America Key Players Scleroderma Therapeutics Market Share (2019-2020)

Table 44. North America Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 45. North America Scleroderma Therapeutics Market Share by Type (2015-2020)

Table 46. North America Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US\$)

Table 47. North America Scleroderma Therapeutics Market Share by Application (2015-2020)

Table 48. Europe Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US\$)

Table 49. Europe Key Players Scleroderma Therapeutics Market Share (2019-2020)

Table 50. Europe Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 51. Europe Scleroderma Therapeutics Market Share by Type (2015-2020)

Table 52. Europe Scleroderma Therapeutics Market Size by Application (2015-2020)
(Million US\$)

Table 53. Europe Scleroderma Therapeutics Market Share by Application (2015-2020)

Table 54. China Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US\$)

Table 55. China Key Players Scleroderma Therapeutics Market Share (2019-2020)

Table 56. China Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 57. China Scleroderma Therapeutics Market Share by Type (2015-2020)

Table 58. China Scleroderma Therapeutics Market Size by Application (2015-2020)
(Million US\$)

Table 59. China Scleroderma Therapeutics Market Share by Application (2015-2020)

Table 60. Japan Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US\$)

Table 61. Japan Key Players Scleroderma Therapeutics Market Share (2019-2020)

Table 62. Japan Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 63. Japan Scleroderma Therapeutics Market Share by Type (2015-2020)

Table 64. Japan Scleroderma Therapeutics Market Size by Application (2015-2020)
(Million US\$)

Table 65. Japan Scleroderma Therapeutics Market Share by Application (2015-2020)

Table 66. Southeast Asia Key Players Scleroderma Therapeutics Revenue (2019-2020)
(Million US\$)

Table 67. Southeast Asia Key Players Scleroderma Therapeutics Market Share
(2019-2020)

Table 68. Southeast Asia Scleroderma Therapeutics Market Size by Type (2015-2020)
(Million US\$)

Table 69. Southeast Asia Scleroderma Therapeutics Market Share by Type
(2015-2020)

Table 70. Southeast Asia Scleroderma Therapeutics Market Size by Application
(2015-2020) (Million US\$)

Table 71. Southeast Asia Scleroderma Therapeutics Market Share by Application
(2015-2020)

Table 72. India Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US\$)

Table 73. India Key Players Scleroderma Therapeutics Market Share (2019-2020)

Table 74. India Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 75. India Scleroderma Therapeutics Market Share by Type (2015-2020)

Table 76. India Scleroderma Therapeutics Market Size by Application (2015-2020)
(Million US\$)

Table 77. India Scleroderma Therapeutics Market Share by Application (2015-2020)

Table 78. Central & South America Key Players Scleroderma Therapeutics Revenue
(2019-2020) (Million US\$)

Table 79. Central & South America Key Players Scleroderma Therapeutics Market
Share (2019-2020)

Table 80. Central & South America Scleroderma Therapeutics Market Size by Type
(2015-2020) (Million US\$)

Table 81. Central & South America Scleroderma Therapeutics Market Share by Type
(2015-2020)

Table 82. Central & South America Scleroderma Therapeutics Market Size by
Application (2015-2020) (Million US\$)

Table 83. Central & South America Scleroderma Therapeutics Market Share by
Application (2015-2020)

Table 84. F. Hoffmann-La Roche AG Company Details

Table 85. F. Hoffmann-La Roche AG Business Overview

Table 86. F. Hoffmann-La Roche AG Product

Table 87. F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business
(2015-2020) (Million US\$)

Table 88. F. Hoffmann-La Roche AG Recent Development

Table 89. Bristol-Myers Squibb Company Company Details

Table 90. Bristol-Myers Squibb Company Business Overview

Table 91. Bristol-Myers Squibb Company Product

Table 92. Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics
Business (2015-2020) (Million US\$)

Table 93. Bristol-Myers Squibb Company Recent Development

Table 94. Celgene Corporation Company Details

Table 95. Celgene Corporation Business Overview

Table 96. Celgene Corporation Product

Table 97. Celgene Corporation Revenue in Scleroderma Therapeutics Business
(2015-2020) (Million US\$)

Table 98. Celgene Corporation Recent Development

Table 99. Argentis Pharmaceuticals, LLC Company Details

Table 100. Argentis Pharmaceuticals, LLC Business Overview

Table 101. Argentis Pharmaceuticals, LLC Product

Table 102. Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics
Business (2015-2020) (Million US\$)

Table 103. Argentis Pharmaceuticals, LLC Recent Development

- Table 104. Bayer AG Company Details
- Table 105. Bayer AG Business Overview
- Table 106. Bayer AG Product
- Table 107. Bayer AG Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)
- Table 108. Bayer AG Recent Development
- Table 109. Boehringer Ingelheim International GmbH Company Details
- Table 110. Boehringer Ingelheim International GmbH Business Overview
- Table 111. Boehringer Ingelheim International GmbH Product
- Table 112. Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)
- Table 113. Boehringer Ingelheim International GmbH Recent Development
- Table 114. Akashi Therapeutics Company Details
- Table 115. Akashi Therapeutics Business Overview
- Table 116. Akashi Therapeutics Product
- Table 117. Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)
- Table 118. Akashi Therapeutics Recent Development
- Table 119. Prometic Life Sciences, Inc. Business Overview
- Table 120. Prometic Life Sciences, Inc. Product
- Table 121. Prometic Life Sciences, Inc. Company Details
- Table 122. Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)
- Table 123. Prometic Life Sciences, Inc. Recent Development
- Table 124. Emerald Health Pharmaceuticals Company Details
- Table 125. Emerald Health Pharmaceuticals Business Overview
- Table 126. Emerald Health Pharmaceuticals Product
- Table 127. Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)
- Table 128. Emerald Health Pharmaceuticals Recent Development
- Table 129. Kadmon Holdings, Inc. Company Details
- Table 130. Kadmon Holdings, Inc. Business Overview
- Table 131. Kadmon Holdings, Inc. Product
- Table 132. Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)
- Table 133. Kadmon Holdings, Inc. Recent Development
- Table 134. Seattle Genetics, Inc. Company Details
- Table 135. Seattle Genetics, Inc. Business Overview
- Table 136. Seattle Genetics, Inc. Product

Table 137. Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)

Table 138. Seattle Genetics, Inc. Recent Development

Table 139. Cytori Therapeutics, Inc. Company Details

Table 140. Cytori Therapeutics, Inc. Business Overview

Table 141. Cytori Therapeutics, Inc. Product

Table 142. Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)

Table 143. Cytori Therapeutics, Inc. Recent Development

Table 144. Fibrocell Science, Inc. Company Details

Table 145. Fibrocell Science, Inc. Business Overview

Table 146. Fibrocell Science, Inc. Product

Table 147. Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)

Table 148. Fibrocell Science, Inc. Recent Development

Table 149. Chemomab Company Details

Table 150. Chemomab Business Overview

Table 151. Chemomab Product

Table 152. Chemomab Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)

Table 153. Chemomab Recent Development

Table 154. Corbus Pharmaceuticals Holdings, Inc. Company Details

Table 155. Corbus Pharmaceuticals Holdings, Inc. Business Overview

Table 156. Corbus Pharmaceuticals Holdings, Inc. Product

Table 157. Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)

Table 158. Corbus Pharmaceuticals Holdings, Inc. Recent Development

Table 159. Genkyotex Company Details

Table 160. Genkyotex Business Overview

Table 161. Genkyotex Product

Table 162. Genkyotex Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US\$)

Table 163. Genkyotex Recent Development

Table 164. Research Programs/Design for This Report

Table 165. Key Data Information from Secondary Sources

Table 166. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Global Scleroderma Therapeutics Market Share by Type: 2020 VS 2026
- Figure 2. Immunosuppressors Features
- Figure 3. Phosphodiesterase 5 Inhibitors - PHA Features
- Figure 4. Endothelin Receptor Antagonists Features
- Figure 5. Prostacyclin Analogues Features
- Figure 6. Calcium Channel Blockers Features
- Figure 7. Analgesics Features
- Figure 8. Others Features
- Figure 9. Global Scleroderma Therapeutics Market Share by Application: 2020 VS 2026
- Figure 10. Systemic Case Studies
- Figure 11. Localized Case Studies
- Figure 12. Scleroderma Therapeutics Report Years Considered
- Figure 13. Global Scleroderma Therapeutics Market Size YoY Growth 2015-2026 (US\$ Million)
- Figure 14. Global Scleroderma Therapeutics Market Share by Regions: 2020 VS 2026
- Figure 15. Global Scleroderma Therapeutics Market Share by Regions (2021-2026)
- Figure 16. Porter's Five Forces Analysis
- Figure 17. Global Scleroderma Therapeutics Market Share by Players in 2019
- Figure 18. Global Top Scleroderma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Therapeutics as of 2019)
- Figure 19. The Top 10 and 5 Players Market Share by Scleroderma Therapeutics Revenue in 2019
- Figure 20. North America Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 21. Europe Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 22. China Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 23. Japan Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 24. Southeast Asia Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 25. India Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 26. Central & South America Scleroderma Therapeutics Market Size YoY

Growth (2015-2020) (Million US\$)

Figure 27. F. Hoffmann-La Roche AG Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 28. F. Hoffmann-La Roche AG Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 29. Bristol-Myers Squibb Company Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 30. Bristol-Myers Squibb Company Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 31. Celgene Corporation Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 32. Celgene Corporation Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 33. Argentis Pharmaceuticals, LLC Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 34. Argentis Pharmaceuticals, LLC Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 35. Bayer AG Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 36. Bayer AG Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 37. Boehringer Ingelheim International GmbH Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 38. Boehringer Ingelheim International GmbH Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 39. Akashi Therapeutics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 40. Akashi Therapeutics Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 41. Prometic Life Sciences, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 42. Prometic Life Sciences, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 43. Emerald Health Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 44. Emerald Health Pharmaceuticals Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 45. Kadmon Holdings, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 46. Kadmon Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 47. Seattle Genetics, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 48. Seattle Genetics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 49. Cytori Therapeutics, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 50. Cytori Therapeutics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 51. Fibrocell Science, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 52. Fibrocell Science, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 53. Chemomab Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 54. Chemomab Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 55. Corbus Pharmaceuticals Holdings, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 56. Corbus Pharmaceuticals Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 57. Genkyotex Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 58. Genkyotex Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

I would like to order

Product name: Covid-19 Impact on Global Scleroderma Therapeutics Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C00E9D3FAA89EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C00E9D3FAA89EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

